Treatment of falciparum malaria with sulfalene and trimethoprim.
D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000962:Antimalarials / Q000627:therapeutic use*; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D005493:Folic Acid Antagonists / Q000627:therapeutic use*; D006801:Humans; D008288:Malaria / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D008297:Male; D010963:Plasmodium falciparum / Q000187:drug effects; D011719:Pyrazines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors; D014295:Trimethoprim / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
D000890:Anti-Infective Agents; D000962:Antimalarials; D004338:Drug Combinations; D005493:Folic Acid Antagonists; D011719:Pyrazines; D011743:Pyrimidines; D013449:Sulfonamides; D014295:Trimethoprim